Results announced from EMPACT-MI phase III trial
Results announced from EMPACT-MI phase III trial in adults following a heart attack.
Search
A day of giving back at Pegasus Therapeutic Riding
Take a look at our volunteer day spent refreshing a farm committed to equine therapy.
Lung Diseases
Our Therapeutic Areas
Retinal Diseases
Retinal Diseases
Boehringer Ingelheim reaches more patients than ever in 2022 as innovative medicines drive growth
Medicines reach record number of people, net sales rise
Oncology & Cancer Immunology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
New analysis confirms OFEV® (nintedanib) slows disease progression in IPF and reduces risk of acute exacerbations
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
INBUILD® meets primary endpoint: study evaluated Ofev® in patients across a range of progressive fibrosing interstitial lung diseases
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
BI initiates Study of Sequencing in EGFR Lung Cancer | BI US
Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.
Boehringer Ingelheim Acquires AMAL Therapeutics
Boehringer Ingelheim Acquires AMAL Therapeutics
Veterinary Public Health
Veterinary Public Health
FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
Our Partners: ViraTherapeutics
Our Partners: ViraTherapeutics
PetPro Connect: Veterinary Medicine in the Digital Age
Read more on PetPro Connect - the BI app & web portal, linking pet owners and veterinarians in a world transformed by digital health and new medicine.
BI Beyond Borders: Science, Collaboration, Geography | BI US
Read more on how the Company’s ‘radar’ for the next big wave of innovation, the RBB team, is tasked with exploring emerging science and technologies.
Bi Inforgraphic biosimilar Data
Dan’s Unique Story
Each cancer journey is unique. In 2018 Dan was diagnosed with a rare form of sarcoma called dedifferentiated liposarcoma. Learn more about Dan’s unique approach to life with DDLPS.
Bringing Value to the Healthcare Community
Our fundamental mission is to make the lives of patients better.
Facing Lung Cancer: Keith’s Story
Facing Lung Cancer: Keith’s Story
Prioritizing mental health and well-being today and every day
Prioritizing Mental Health and Well-being Today and Everyday
Welcome to Innovation @ Boehringer Ingelheim
Welcome to Innovation @ Boehringer Ingelheim
History of our Logo | Corporate Profile | Boehringer Ingelheim US
The logo used by Boehringer Ingelheim today is a stylized depiction of the central section of the imperial palace of Charlemagne.
Welcome to Animal Health Partnering
Welcome to Animal Health Partnering
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison
Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison